Skip to main content
Fig. 2 | Pediatric Rheumatology

Fig. 2

From: Retrospective case series describing the efficacy, safety and cost-effectiveness of a vial-sharing programme for canakinumab treatment for paediatric patients with cryopyrin-associated periodic syndrome

Fig. 2

Serum Amyloid A levels score pre-and post canakinumab. Serological response was monitored using serum amyloid A (SAA, reference range < 10 mg/L). The figure shows that the median SAA before treatment was 34.8 mg/L (range 0–497; reference range [RR] less than 10 mg/L); and SAA was raised (higher than upper RR) in 11/20 (55%) patients (Fig. 2)

Back to article page